Trends in transmission of drug resistance and prevalence of Non-B subtypes in patients with acute or recent HIV-1 infection in Barcelona in the last 16 years (1997-2012)

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Ambrosioni, Juan ^a   Sued, Omar ^b   Nicolas, David ^a   Parera, Marta ^a   López Diéguez, María ^a   Romero, Anabel ^c   Agüero, Fernando ^a   Marcos, María Ángeles ^a,d   Manzardo, Christian ^a   Zamora, Laura ^a   Gómez Carrillo, Manuel ^e   Gatell, José María ^a   Pumarola, Tomás ^a   Miró, JoséMaría Miró ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Huesped Foundation   (Argentina)

^c Agency for Healthcare Quality and Assessment of Catalonia (AQuAS)   (Spain)

^d CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^e Institute for Biomedical Research in Retroviruses and AIDS   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; COHORT ANALYSIS; FEMALE; GENE MUTATION; GENOTYPE; HOSPITAL CARE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMIGRANT; MAJOR CLINICAL STUDY; MALE; MEN WHO HAVE SEX WITH MEN; PHYLOGENY; PREVALENCE; SPAIN; TREND STUDY; VIRUS GENE; VIRUS TRANSMISSION; ACUTE DISEASE; GENETICS; HIV INFECTIONS; MIDDLE AGED; MUTATION; PATHOGENICITY; RETROSPECTIVE STUDY; TRANSMISSION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ACUTE DISEASE; ADULT; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION; PHYLOGENY; PREVALENCE; RETROSPECTIVE STUDIES; SPAIN;

EID: 84931282171     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0125837     Document Type: Article

References (42)

1. Harrigan PR, Hogg RS, Dong WW, Yip B, Wynhoven B, Woodward J, et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis 2005; 191:339-347. PMID: 15633092
2. Booth CL, Geretti AM. Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection. J Antimicrob Chemother 2007; 59:1047-1056.
3. Girardi E. Epidemiological aspects of transmitted HIV drug resistance. Scand J Infect Dis Suppl 2003; 106:17-20. PMID: 15000576
4. Hecht FM, Wang L, Collier A, Little S, Markowitz M, Margolick J, et al. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection. J Infect Dis 2006; 194:725-733. PMID: 16941337
5. Smith D, Moini N, Pesano R, Cachay E, Aiem H, Lie Y, et al. Clinical utility of HIV standard genotyping among antiretroviral-naive individuals with unknown duration of infection. Clin Infect Dis 2007; 44:456-458. PMID: 17205459
6. de MC, Rodriguez C, Colomina J, Tuset C, Garcia F, Eiros JM, et al. Resistance to nonnucleoside reverse-transcriptase inhibitors and prevalence of HIV type 1 non-B subtypes are increasing among persons with recent infection in Spain. Clin Infect Dis 2005; 41:1350-1354. PMID: 16206115
7. Palacios R, Viciana I, Perez dP I, de la Torre J, Ropero F, Fernandez S, et al. [Prevalence of primary resistance mutations in patients with newly diagnosed HIV infection in the province of Malaga (Spain)]. Enferm Infecc Microbiol Clin 2008; 26:141-145. PMID: 18358212
8. Holguin A, de MM, Yebra G, Lopez M, Soriano V. Increase of non-B subtypes and recombinants among newly diagnosed HIV-1 native Spaniards and immigrants in Spain. Curr HIV Res 2008; 6:327-334. PMID: 18691031
9. Yebra G, de MM, Martin L, Rodriguez C, Labarga P, Viciana I, et al. Most HIV type 1 non-B infections in the Spanish cohort of antiretroviral treatment-naive HIV-infected patients (CoRIS) are due to recombinant viruses. J Clin Microbiol 2012; 50:407-413.
10. Tamura K, Stecher G, Peterson D, Filipski A, Kumar S. MEGA6: Molecular Evolutionary Genetics Analysis version 6.0. Mol Biol Evol 2013; 30:2725-2729. doi: 10.1093/molbev/mst197 PMID: 24132122
11. Lole KS, Bollinger RC, Paranjape RS, Gadkari D, Kulkarni SS, Novak NG, et al. Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. J Virol 1999; 73:152-160. PMID: 9847317
12. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 2009; 4:e4724. doi: 10.1371/journal.pone.0004724 PMID: 19266092
13. Yebra G, Holguin A. [Epidemiology of drug-resistant HIV-1 transmission in naive patients in Spain]. Med Clin (Barc) 2010; 135:561-567. doi: 10.1016/j.medcli.2009.09.029 PMID: 19959197
14. de Mendoza C, Rodriguez C, Eiros JM, Colomina J, Garcia F, Leiva P, et al. Antiretroviral recommendations may influence the rate of transmission of drug-resistant HIV type 1. Clin Infect Dis 2005; 41:227-232. PMID: 15983920
15. Ambrosioni J, Nicolas D, Sued O, Aguero F, Manzardo C, Miro JM. Update on antiretroviral treatment during primary HIV infection. Expert Rev Anti Infect Ther 2014; 12:793-807. doi: 10.1586/14787210.2014.913981 PMID: 24803105
16. Ambrosioni J, Junier T, Delhumeau C, Calmy A, Hirschel B, Zdobnov E, et al. Impact of highly active antiretroviral therapy on the molecular epidemiology of newly diagnosed HIV infections. AIDS 2012; 26:2079-2086. doi: 10.1097/QAD.0b013e32835805b6 PMID: 23052354
17. Ambrosioni J, Calmy A, Hirschel B. HIV treatment for prevention. J Int AIDS Soc 2011; 14:28. doi: 10.1186/1758-2652-14-28 PMID: 21612619
18. th European HIVDrugResistanceWorkshop.2009 Mar 25-27, Stockholm, Sweeden.
19. Yebra G, de MM, del RJ, Rodriguez C, Holguin A. HIV-1 non-B subtypes: High transmitted NNRTI-resistance in Spain and impaired genotypic resistance interpretation due to variability. Antiviral Res 2010; 85:409-417. doi: 10.1016/j.antiviral.2009.11.010 PMID: 20004217
20. Monge S, Guillot V, Alvarez M, Chueca N, Stella N, Pena A, et al. Clinically relevant transmitted drug resistance to first line antiretroviral drugs and implications for recommendations. PLoS One 2014; 9: e90710. doi: 10.1371/journal.pone.0090710 PMID: 24637804
21. Descamps D, Chaix ML, Andre P, Brodard V, Cottalorda J, Deveau C, et al. French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviralnaive chronically infected patients in 2001-2002. J Acquir Immune Defic Syndr 2005; 38:545-552. PMID: 15793364
22. Violin M, Velleca R, Cozzi-Lepri A, Riva C, Grossi PA, Carnevale G, et al. Prevalence of HIV-1 primary drug resistance in seroconverters of the ICoNA cohort over the period 1996-2001. J Acquir Immune Defic Syndr 2004; 36:761-764. PMID: 15167299
23. Descamps D, Assoumou L, Chaix ML, Chaillon A, Pakianather S, de RA, et al. National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001-2011. J Antimicrob Chemother 2013; 68:2626-2631. doi: 10.1093/jac/dkt238 PMID: 23798669
24. Zu KF, Scheufele R, Kucherer C, Jansen K, Somogyi S, Dupke S, et al. First Line Treatment Response in Patients with Transmitted HIV Drug Resistance and Well Defined Time Point of HIV Infection: Updated Results from the German HIV-1 Seroconverter Study. PLoS One 2014; 9:e95956. doi: 10.1371/journal.pone.0095956 PMID: 24788613
25. Wensing AM, Van de Vijver DA, Angarano G, Asjo B, Balotta C, Boeri E, et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 2005; 192:958-966. PMID: 16107947
26. Vercauteren J, Wensing AM, Van de Vijver DA, Albert J, Balotta C, Hamouda O, et al. Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis 2009; 200:1503-1508. doi: 10.1086/644505 PMID: 19835478
27. Wittkop L, Gunthard HF, de WF, Dunn D, Cozzi-Lepri A, De LA, et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis 2011; 11:363-371. doi: 10.1016/S1473-3099(11)70032-9 PMID: 21354861
28. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347:385-394.
29. Wheeler WH, Ziebell RA, Zabina H, Pieniazek D, Prejean J, Bodnar UR, et al. Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006. AIDS 2010; 24:1203-1212.
30. th Conference on Retroviruses and Opportunistic Infections, San Francisco. 2010;Paper #580.
31. Castor D, Low A, Evering T, Karmon S, Davis B, Figueroa A, et al. Transmitted drug resistance and phylogenetic relationships among acute and early HIV-1-infected individuals in New York City. J Acquir Immune Defic Syndr 2012; 61:1-8.
32. Weinstock HS, Zaidi I, Heneine W, Bennett D, Garcia-Lerma JG, Douglas JM Jr., et al. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis 2004; 189:2174-2180. PMID: 15181563
33. Ambrosioni J, Nicolas D, Aguero F, Manzardo C, Miro JM. HIV treatment outcomes in Europe and North America: what can we learn from the differences? Expert Rev Anti Infect Ther 2014; 12:523-526. doi: 10.1586/14787210.2014.906900 PMID: 24694073
34. Barbour JD, Hecht FM, Wrin T, Liegler TJ, Ramstead CA, Busch MP, et al. Persistence of primary drug resistance among recently HIV-1 infected adults. AIDS 2004; 18(12):1683-1689. PMID: 15280779
35. Pao D, Andrady U, Clarke J, Dean G, Drake S, Fisher M, et al. Long-term persistence of primary genotypic resistance after HIV-1 seroconversion. J Acquir Immune Defic Syndr 2004; 37:1570-1573. PMID: 15577410
36. Metzner KJ, Scherrer AU, Preiswerk B, Joos B, von W, V, Leemann C, et al. Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection. J Infect Dis 2013; 208:1102-1112. doi: 10.1093/infdis/jit310 PMID: 23847055
37. Chaix ML, Seng R, Frange P, Tran L, Avettand-Fenoel V, Ghosn J, et al. Increasing HIV-1 non-B subtype primary infections in patients in France and effect of HIV subtypes on virological and immunological responses to combined antiretroviral therapy. Clin Infect Dis 2013; 56:880-887. doi: 10.1093/cid/cis999 PMID: 23223603
38. Ciccozzi M, Santoro MM, Giovanetti M, Andrissi L, Bertoli A, Ciotti M. HIV-1 non-B subtypes in Italy: a growing trend. New Microbiol 2012; 35:377-386. PMID: 23109005
39. Jorgensen LB, Christensen MB, Gerstoft J, Mathiesen LR, Obel N, Pedersen C, et al. Prevalence of drug resistance mutations and non-B subtypes in newly diagnosed HIV-1 patients in Denmark. Scand J Infect Dis 2003; 35:800-807. PMID: 14723353
40. Lospitao E, Alvarez A, Soriano V, Holguin A. HIV-1 subtypes in Spain: a retrospective analysis from 1995 to 2003. HIV Med 2005; 6:313-320. PMID: 16156878
41. Perez-Alvarez L, Carmona R, Munoz M, Delgado E, Thomson MM, Contreras G, et al. High incidence of non-B and recombinant HIV-1 strains in newly diagnosed patients in Galicia, Spain: study of genotypic resistance. Antivir Ther 2003; 8:355-360. PMID: 14518705
42. Pernas B, Grandal M, Mena A, Castro-Iglesias A, Canizares A, Wyles DL, et al. High prevalence of subtype F in newly diagnosed HIV-1 persons in northwest Spain and evidence for impaired treatment response. AIDS 2014; 28:1837-1840.